Purchase Order 75N98026P00071
Award Date 3/9/26
Potential Completion Date 11/8/26
Potential Value $224K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $14,924.64, is for the provision of INTERCEPT Blood System equipment, illuminator maintenance services, and specialized pathogen reduction technology products. The contract has a performance period ending on June 7, 2025. Cerus...
- The National Institutes of Health (NIH) awarded a $28,924.80 firm fixed price purchase order contract to Cerus Corporation for the delivery of INTERCEPT Platelet Processing Sets with Dual Storage Containers. This sole-source contract is for the Department of Transfusion Medicine and will run from April 1, 2025 to September 30, 2025. Cerus Corporation's proprietary INTERCEPT technology is used to reduce the potential for virus replication in platelets, ensuring the safety of transfused blood...
- This federal contract award is for the procurement of INTERCEPT Platelet Processing Sets by the National Institutes of Health (NIH) Clinical Center, a civilian agency. The $115,699.20 firm fixed-price purchase order was awarded to Cerus Corporation, a for-profit manufacturer of biomedical products specializing in blood safety technologies. The contract has an ultimate completion date of September 30, 2025 and does not have a set-aside designation. Cerus Corporation is the prime contractor and...
- This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
- This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- This federal contract award with ID 75A50124C00046 was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation, a for-profit manufacturer. The $188,446,002.15 cost-sharing contract is for the license of Cerus' proprietary Pathogen Reduction Technology (PRT) for red blood cell (RBC) components, with the goal of reducing the risk of transfusion-transmitted infections by recognized, emerging, epidemic, and endemic pathogens. This...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- The Defense Health Agency awarded Cerus Corporation a firm fixed-price purchase order valued at $367.1K on October 1, 2025, for Cerus Intercept Platelet Processing Sets. The contract, which has no set-aside designation, originated from a sources sought notice posted by Tripler Army Medical Center seeking specialized blood processing equipment utilizing the INTERCEPT Blood System technology. This system employs amotosalen, a photoactive compound that uses UVA illumination to inactivate...